Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Clearmind Medicine Inc (NQ: CMND )

1.540 +0.140 (+10.00%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Clearmind Medicine Inc

< Previous 1 2 3 4 Next >
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Applies to Cease Being a Reporting Issuer in Canada
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine CEO Issues Letter to Shareholders
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
From SciSparc Ltd
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.